1 |
Norwood DA, Montalvan-Sanchez E, Dominguez RL, et al. Gastric Cancer: Emerging Trends in Prevention, Diagnosis, and Treatment[J]. Gastroenterol Clin North Am, 2022, 51(3):501-518.
|
2 |
Kodera Y, Yoshida K, Kochi M, et al. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study[J]. Gastric Cancer, 2023, 26(6):1063-1068.
|
3 |
Wang H, Yang L, Liu R, et al. ADAR1 affects gastric cancer cell metastasis and reverses cisplatin resistance through AZIN1[J]. Anticancer Drugs, 2023, 34(10):1132-1145.
|
4 |
Aalami AH, Aalami F, Sahebkar A. Gastric Cancer and Circulating microRNAs: An Updated Systematic Review and Diagnostic Meta-Analysis[J]. Curr Med Chem, 2023, 30(33):3798-3814.
|
5 |
Liu C, Li S, Tang Y. Mechanism of cisplatin resistance in gastric cancer and associated microRNAs[J]. Cancer Chemother Pharmacol, 2023, 92(5):329-340.
|
6 |
Zhang, Kang, Lu, et al. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway[J]. Cell Cycle, 2018, 17(15): 1886–1900.
|
7 |
Zhang Z, Zhou Q, Luo F, et al. Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis[J]. Hum Cell, 2021, 34(5):1558-1568.
|
8 |
Liu F, Ma J, Wang K, et al. High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma[J]. J Cancer, 2019, 10(25):6252-6260.
|
9 |
Peng QP, Du DB, Ming Q, et al. MicroRNA 494 increases chemosensitivity to doxorubicin in gastric cancer cells by targeting phosphodiesterases 4D[J]. Cell Mol Biol (Noisy-le-grand), 2018, 64(15):62-66.
|
10 |
徐龙健,高建超,钟轩,等. 微小RNA-876-3p靶向肽基脯氨酰顺反异构酶A调控胃癌细胞增殖和顺铂耐药性的作用机制研究[J]. 中国临床药理学杂志, 2020, 36(17):2686-2690.
|
11 |
Dai X, Chen Y, Chen N, et al. KLF5-mediated aquaporin 3 activated autophagy to facilitate cisplatin resistance of gastric cancer[J]. Immunopharmacol Immunotoxicol, 2023, 45(2):140-152.
|
12 |
Chen W, Hu J, He Y, et al. The Interaction Between SMAD1 and YAP1 Is Correlated with Increased Resistance of Gastric Cancer Cells to Cisplatin[J]. Appl Biochem Biotechnol, 2023, 195(10):6050-6067.
|
13 |
Zhou C, Chen L, Chen R, et al. miR-4486 enhances cisplatin sensitivity of gastric cancer cells by restraining the JAK3/STAT3 signalling pathway[J]. J Chemother, 2022, 34(1):35-44.
|
14 |
Zhu T, Hu Z, Wang Z, et al. microRNA-301b-3p from mesenchymal stem cells-derived extracellular vesicles inhibits TXNIP to promote multidrug resistance of gastric cancer cells[J]. Cell Biol Toxicol, 2023, 39(5):1923-1937.
|
15 |
Cui F, Hao ZX, Li J, et al. SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p[J]. Mol Genet Genomic Med, 2020, 8(5):e1195. doi: 10.1002/mgg3.1195.
|
16 |
Song L, Duan P, Gan Y, et al. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma[J]. Braz J Med Biol Res, 2017, 50(5):e6359. doi: 10.1590/1414-431X20176359.
|
17 |
Hsien Lai S, Zervoudakis G, Chou J, et al. PDE4 subtypes in cancer[J]. Oncogene, 2020, 39(19):3791-3802.
|
18 |
Delyon J, Servy A, Laugier F, et al. PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma[J]. Oncogene, 2017, 36(23):3252-3262.
|
19 |
Cao B, Wang K, Liao JM, et al. Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation[J]. Elife, 2016, 5:e15978. doi: 10.7554/eLife.15978.
|
20 |
Zuo Y, Zheng W, Liu J, et al. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells[J]. Neoplasma, 2020, 67(1):93-101.
|
21 |
Wang C, Wang S, Ma F, et al. miRNA-328 overexpression confers cisplatin resistance in non-small cell lung cancer via targeting of PTEN[J]. Mol Med Rep, 2018, 18(5):4563-4570.
|
22 |
Cao M, Nawalaniec K, Ajay AK,et al. PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner[J]. Transl Oncol, 2022, 19(1):101377. doi: 10.1016/j.tranon.2022.101377.
|
23 |
Mishra RR, Belder N, Ansari SA, et al. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer[J]. Clin Cancer Res, 2018, 24(8):1987-2001.
|